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Abstract
Purpose Eight of the ten items of the Dermatology Life Quality Index (DLQI) have a ‘not relevant’ response (NRR) option. 
There are two possible ways to interpret NRRs: they may be considered ‘not at all’ or missing responses. We aim to compare 
the measurement performance of the DLQI in psoriasis patients when NRRs are scored as ‘0’ (hereafter zero-scoring) and 
‘missing’ (hereafter missing-scoring) using Rasch model analysis.
Methods Data of 425 patients with psoriasis from two earlier cross-sectional surveys were re-analysed. All patients com-
pleted the paper-based Hungarian version of the DLQI. A partial credit model was applied. The following model assumptions 
and measurement properties were tested: dimensionality, item fit, person reliability, order of response options and differential 
item functioning (DIF).
Results Principal component analysis of the residuals of the Rasch model confirmed the unidimensional structure of the 
DLQI. Person separation reliability indices were similar with zero-scoring (0.910) and missing-scoring (0.914) NRRs. With 
zero-scoring, items 6 (sport), 7 (working/studying) and 9 (sexual difficulties) suffered from item misfit and item-level disor-
dering. With missing-scoring, no misfit was observed and only item 7 was illogically ordered. Six and three items showed 
DIF for gender and age, respectively, that were reduced to four and three by missing-scoring.
Conclusions Missing-scoring NRRs resulted in an improved measurement performance of the scale. DLQI scores of patients 
with at least one vs. no NRRs cannot be directly compared. Our findings provide further empirical support to the DLQI-R 
scoring modification that treats NRRs as missing and replaces them with the average score of the relevant items.
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Introduction
The Dermatology Life Quality Index (DLQI) is the most 
frequent health-related quality of life (HRQoL) measure in 
patients with psoriasis, used in a range of settings, includ-
ing consultations, clinical trials as well as for treatment 
decisions [1, 2]. It is the most commonly used HRQoL 
instrument in randomised controlled trials for psoriasis 
[3]. In clinical guidelines, DLQI along with Psoriasis Area 
and Severity Index (PASI) is considered a useful bench-
mark to define moderate-to-severe psoriasis, to set out eli-
gibility criteria for systemic treatments, including biolog-
ics, and to evaluate the effectiveness of treatments [4–6]. 
The DLQI has been translated to over 100 languages, and 
a recent study found 40 some countries using the DLQI in 
their national psoriasis treatment guidelines and/or reg-
istries [7].
In spite of the nearly three decades of experience accu-
mulated with the DLQI, the dermatological community 
has just recently started to study the matter of ‘not rel-
evant’ responses (NRRs) on the DLQI. Studies from the 
US and Europe reported that one or more items of the 
DLQI are irrelevant for 22.1–48.0% of psoriasis patients 
[8]. Prior work suggests that female gender, lower educa-
tion level, single, widowed or divorced marital status and 
unemployed or disabled employment status were asso-
ciated with increased odds of having at least one NRR 
[8–11]. It has also been described that psoriasis patients 
who responded ‘not relevant’ had more severe disease than 
those who responded ‘not at all’ in questionnaire items [9].
NRRs appear in eight of the 10 items on the DLQI. These 
items are related to the following areas of HRQoL: shop-
ping/home/gardening, clothing, social/leisure activities, 
sport, working/studying, interpersonal problems, sexual dif-
ficulties and treatment difficulties. There are two possibili-
ties to interpret NRRs (Fig. 1). Let us take the example of a 
patient that is not practicing any sports, therefore responds 
‘not relevant’ to item 6 (sport) on the DLQI. According to 
the first interpretation of the NRR – that is also in line with 
the official scoring of the DLQI – there is no sport-related 
impact of the skin condition on this patient’s HRQoL that 
should be considered equivalent to a ‘not at all’ response and 
scored as ‘0′ (hereafter referred to as zero-scoring). The sec-
ond interpretation is to consider that as sport is not relevant 
to the patient it is unknown what the sport-related HRQoL 
impact of the skin condition would have had if sport had 
been relevant to this patient. In this second approach, the 
Fig.1  The two possible 
interpretations of ‘not rel-
evant’ responses on the DLQI. 
DLQI Dermatology Life Quality 
Index, HRQoL health-related 
quality of life
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response does not provide any information on the measured 
concept, and thus, is considered as a missing response (here-
after referred to as missing-scoring). This second interpre-
tation of the NRR is well aligned with the DLQI-Relevant 
(DLQI-R) scoring modification of the DLQI that treats 
NRRs as missing and replaces them with the average score 
of the relevant items [12].
The two parallel existing interpretations of the NRR 
option may compromise the comparability of responses and 
DLQI scores across patients. DLQI scores obtained with one 
or several NRRs may not be compared to the DLQI scores 
obtained on a full set of ‘relevant’ responses. Moreover, if 
two different items are not relevant to two different patients, 
it is unclear if comparability of their scores may be ensured.
All previous studies focusing on NRRs applied classical 
test theory as a framework to guide validation [9–11, 13]. An 
alternative measurement approach, a Rasch model analysis, 
may offer numerous advantages over classical test theory 
in evaluating psychometric performance of scales [14]. So 
far, a small number of studies have applied Rasch models to 
examine the psychometric properties of the DLQI in various 
skin diseases [15–21]; however, only one study concerned 
with psoriasis alone, and no studies differentiated between 
the two possible interpretations of NRRs. The objective of 
this study is therefore to (i) evaluate the psychometric prop-
erties of the DLQI in patients with psoriasis using a Rasch 
model analysis and (ii) to compare the measurement perfor-
mance of DLQI when NRRs are scored as ‘0′ and ‘missing’.
Methods
Study design and patients
Data from two cross-sectional questionnaire surveys among 
psoriasis patients were pooled for this study. These surveys 
have been undertaken at two university dermatology clinics 
in Hungary. Eligible patients were 18 years or older, diag-
nosed with psoriasis by a dermatologist and able to under-
stand and complete the questionnaire. In the first survey, 
patients had to meet further eligibility criteria, including 
having moderate-to-severe psoriasis or having been treated 
with systemic non-biological or biological therapy for at 
least 12 months before the survey [22]. Diagnosis of mod-
erate-to-severe psoriasis was established based on the defi-
nition of the European consensus: [body surface area > 10 
or Psoriasis Area and Severity Index (PASI) > 10] and 
DLQI > 10 [4]. The second survey recruited both in- and 
outpatients regardless of disease severity [23]. There were 
no exclusion criteria other than failure to meet the inclusion 
criteria.
The dataset included patients’ DLQI responses, 
PASI score and the following demographic and clinical 
characteristics: age, gender, disease duration, clinical sub-
type and treatment at the time of the survey.
Dermatology Life Quality Index (DLQI)
DLQI is intended to assess the HRQoL impairment of adult 
patients (aged ≥ 16 years) on the preceding week. It has 10 
items covering the following six aspects of HRQoL: symp-
toms and feelings, daily activities, leisure, work/school, per-
sonal relationships, and treatment. Each item is answered on 
a 4-point scale scored as follows: ‘not at all’ = 0, ‘a little’ = 1, 
‘a lot’ = 2 and ‘very much’ = 3. NRR options are available 
for items 3–10. Item scores are added up to give a minimum 
score of 0 and maximum score of 30, where a higher DLQI 
total score indicates a greater degree of HRQoL impairment. 
The Hungarian version of the paper-based DLQI was used 
in the surveys.
Rasch model
The Rasch model is a mathematical model that describes 
the relationship between individuals’ ‘latent trait’ (i.e. 
impairment in HRQoL) and how they respond to items on 
a scale. A polytomous Rasch model (partial credit model) 
was applied to analyse the psychometric properties of the 
DLQI [24]. First, we used a likelihood-ratio test to deter-
mine whether the rating scale or the partial credit model 
with conditional likelihood estimation was most appropriate 
[25]. We tested the following key assumptions and prop-
erties of the Rasch model: dimensionality, item fit, person 
reliability, order of response options and item invariance. 
A person-item map was depicted to place both persons and 
items on the same interval-level scale, so that they can be 
compared [26]. Two separate analyses were carried out with 
zero-scoring and missing-scoring NRRs, respectively. By 
missing-scoring each NRR, we took advantage of the ability 
of the Rasch model to handle missing responses by simply 
not including that item for that patient in the estimation.
Dimensionality
To analyse dimensionality, we performed a principal com-
ponent analysis (PCA) using orthogonal varimax rotation 
on the standardized residuals of the Rasch model. Residuals 
were defined as the discrepancy between the observed and 
predicted values of the model. The DLQI was considered 
unidimensional if all 10 items underlined the same latent 
trait. A possible presence of additional dimensions was con-
sidered when the eigenvalues of the residual components 
were ≥ 2 [27]. Response dependency was evaluated via 
the correlation between the items’ standardized residuals, 
whereby correlation coefficients of 0.3 and above were con-
sidered unacceptable [28].
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Person separation reliability
In order to determine the internal reliability of the DLQI 
in differentiating between patients with different level of 
HRQoL impairment, we computed person separation reli-
ability. Values range from 0 to 1, where a separation reli-
ability value of > 0.8 indicates an acceptable reliability [27].
Item fit
The fit of the data to the Rasch model was investigated with 
reference to χ2-fit [29] and infit and outfit unstandardized 
mean square (MNSQ) statistics. A significant χ2-fit statistic 
indicates misfit to the model. The infit and outfit MNSQ val-
ues range between zero and positive infinity, where 1 indi-
cates a perfect fit of data to the Rasch model. Infit and outfit 
MNSQ values ranging between 0.5 and 1.5 are considered 
indicative of a well-fitting model [30, 31]. A lower value 
suggests overfit between the items and the model (i.e. items 
are too discriminating) and a higher value indicates underfit 
(i.e. unpredictability of data).
Order of response options
Response options of DLQI items (scored from 0 to 3) are 
expected to follow each other in a monotonic order; thus, 
ranging from the least severe to the most severe. In other 
words, the more problems with HRQoL patients have in a 
certain item, the higher their probability of endorsing it is. 
This relationship between HRQoL impairment of patients 
and their responses on DLQI items was depicted by item 
characteristic curves (ICCs).
Item invariance
A lack of item invariance [i.e. differential item functioning 
(DIF)] means that different subgroups respond differently 
to certain DLQI items, after controlling for differences in 
patients’ overall HRQoL [32]. Two types of DIF can be 
identified: uniform DIF that is constant across ability levels 
and non-uniform DIF that varies across ability levels. The 
presence of DIF was assessed across gender (female or male) 
and age [below or above median age (49 years)] by applying 
a likelihood-ratio test [33, 34].
For all analyses a p < 0.05 was considered statistically 
significant. The Rasch model analysis was undertaken using 
the eRM package in R version 3.6.1 (Vienna, Austria) [35, 
36] and differential item functioning was tested using the 
DIFLRT macro [37] in IBM SPSS Statistics for Windows, 
version 25.0 (IBM Corp., Armonk, N.Y., USA).
Results
Patient population
Overall, 436 patients with psoriasis participated in the two 
surveys. Data of 11 patients with missing responses on one 
or more DLQI items were excluded, and as a result, the final 
sample consisted of 425 patients. Nearly two-thirds of the 
patients (64.9%) were male (Table 1). Patients’ age ranged 
between 18 and 86 years, with a mean of 49.2 ± 14.3 years. 
Mean disease duration was 19.8 ± 12.2 years. The most 
Table 1  Characteristics of the psoriasis patient population (n = 425)
DLQI Dermatology Life Quality Index, PASI Psoriasis Area and 
Severity Index
a: Combinations are possible
b: DLQI scores are categorised according to the Hongbo’s DLQI 
score bands [56]
Variables Mean (SD) or n (%)
Age (years) 49.2 (14.3)





 Chronic plaque psoriasis 312 (73.4%)
 Erythrodermic 7 (1.6%)









 Topical (only) 103 (24.2%)
 Systemic non-biological 107 (25.2%)
 Biological 184 (43.3%)
Disease severity (PASI 0–72)
 Mean 8.4 (9.5)
 PASI ≤ 10 143 (33.6%)
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common clinical subtypes were chronic plaque psoriasis 
(73.4%), scalp psoriasis (48.2%) and nail psoriasis (45.6%). 
Over one-third of the patients were diagnosed with psoriatic 
arthritis (35.8%). The proportion of patients with a PASI 
score ≥ 10 was 66.4%.
Item descriptives
Mean DLQI score was 6.8 ± 7.4. Overall, 113 patients 
(26.6%) had a DLQI score of zero, while two patients (0.5%) 
achieved the maximum of 30 points. A total of 84 (19.8%) 
patients had one, 49 (11.5%) had two, 22 (5.2%) had three, 7 
(1.6%) had four, and 4 (0.9%) had over four NRRs. Relative 
frequencies of responses on the 10 items of the DLQI are 
provided in Fig. 2. The largest proportion of NRRs occurred 
in items 6 (sport), 9 (sexual difficulties) and 7 (working/
studying).
Dimensionality
PCA on the residuals of the Rasch model revealed one factor 
explaining 60.9% of the variance in DLQI. All the eigenval-
ues of the residuals (range 0.160–1.699) of the latent trait 
were < 2, and the correlations between the items’ standard-
ized residuals (range │0.001│–│0.282│) were below 0.3 
supporting the unidimensional construct of the DLQI.
Person separation reliability
Person separation reliability values for the DLQI were 
slightly better (0.914) with missing-scoring in comparison 
with zero-scoring NRRs (0.910).
Person and item fit
Overall, 3.76% and 2.90% of patients misfitted the Rasch 
model when NRRs were scored as ‘0′ and missing, respec-
tively. With zero-scoring NRRs, the χ2 fit statistic detected 
three items to misfit to the Rasch model: items 6 (sport) 
(p < 0.001), 7 (working/studying) (p = 0.034) and item 9 
(sexual difficulties) (p = 0.0498) (Table 2). No items mis-
fitted to the model in case of scoring NRRs as missing. 
With zero-scoring, the outfit and infit MNSQ statistics 
ranged between 0.564 [item 5 (social/leisure activities)] to 
1.378 [item 6 (sport)] and between 0.611 [item 5 (social/
leisure activities)] to 1.212 [item 9 (sexual difficulties)], 
respectively. With missing-scoring, the outfit and infit 
MNSQ statistics were between 0.561 [item 5 (social/lei-
sure activities)] and 1.131 [item 7 (working/studying)] and 
0.598 [item 5 (social/leisure activities)] and 1.291 [item 9 
(sexual difficulties)], respectively. These values are within 
the range of the commonly accepted cut-offs (0.5–1.5).
Order of response options
When zero-scoring, response thresholds were disordered 
for items 6 (sport), 7 (working/studying) and 9 (sexual 
difficulties) (Fig. 3). Response options 1 (‘a little’) and 
2 (‘a lot’) did not follow the monotonic order for items 
6 (sport) and 9 (sexual difficulties), and 2 (‘a lot’) and 3 
(‘very much’) for item 7 (working/studying). Conversely, 
with missing-scoring NRRs, only response options 2 (‘a 
lot’) and 3 (‘very much’) were illogically ordered for item 
7 (working/studying).
Fig.2  Distribution of responses 
on the 10 items of the DLQI 
ordered in relation to their 
proportion of ‘not relevant’ 
responses (n = 425). Item 
1 = itchy/sore/painful/stinging; 
Item 2 = embarrassed/self con-
scious; Item 3 = shopping/home/
gardening; Item 4 = clothes; 
Item 5 = social/leisure activities; 
Item 6 = sport; Item 7 = work-
ing/studying; Item 8 = interper-
sonal problems; Item 9 = sexual 
difficulties; Item 10 = treatment 
difficulties. DLQI Dermatology 
Life Quality Index
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Person‑item map
In case of zero-scoring NRRs, item locations ranged 
from -0.27 to 1.94 logits, where item 1 (itchy/sore/pain-
ful/stinging) and 9 (sexual difficulties) were the least and 
most difficult (i.e. required the least and the most HRQoL 
impairment to endorse the item). Overall, examination of 
the person-item map suggests adequate coverage of items 
around the middle range of latent trait, but regardless of 
how NRRs were interpreted, a large proportion of patients 
had a high probability for low scores (Fig. 4). With zero-
scoring NRRs, the locations of items 6 (sport), 7 (working/
studying) and 8 (interpersonal problems) were very close 
to each other (0.736, 0.793 and 0.743) suggesting an item 
redundancy. With missing-scoring, location of item 3 
(shopping/home/gardening) was very close to that of item 
9 (sexual difficulties) (1.110 vs. 1.095), and location of 
item 4 (clothing) to that of item 10 (treatment difficul-
ties) (-0.038 vs. 0.001). The order of difficulty of the 10 
items was similar with the two scoring methods. The four 
most difficult items were 9 (sexual difficulties), 3 (shop-
ping/home/gardening), 7 (working/studying) and 8 (inter-
personal problems) with zero-scoring NRRs, whereas 
3 (shopping/home/gardening), 9 (sexual difficulties), 8 
Table 2  Item locations, fit statistics and DIF of DLQI items
Coding of variables: Age: 0 =  < 49 years (median age), 1 =  ≥ 49 years
DIF differential item functioning, DLQI Dermatology Life Quality Index, MNSQ unstandardized mean square statistics, NRR ‘not relevant’ 
response, nU non-uniform DIF, U uniform DIF
Items Item location 
(difficulty)
Item fit Differential item func-
tioning (DIF)
χ2 df p-value MNSQ (outfit) MNSQ (infit) DIF No DIF
NRRs coded as ‘0’
 Item 1 (itchy/sore/painful/stinging) − 0.871 343.7 309 0.085 1.109 1.098 Age (nU) Gender
 Item 2 (embarrassed/self conscious) − 0.418 228.8 309 1.000 0.738 0.760 Gender (U) Age
 Item 3 (shopping/home/gardening) 0.882 199.8 309 1.000 0.645 0.717 Age (U)
Gender (U)
–
 Item 4 (clothes) − 0.205 290.4 309 0.770 0.937 0.891 Gender (U) Age
 Item 5 (social/leisure activities) 0.049 174.9 309 1.000 0.564 0.611 Gender (U) Age
 Item 6 (sport) 0.736 427.3 309  < 0.001 1.378 1.066 Age (U)
Gender (U)
–
 Item 7 (working/studying) 0.793 355.9 309 0.034 1.148 1.050 – Age
Gender
 Item 8 (interpersonal problems) 0.743 248.5 309 0.995 0.802 0.880 – Age
Gender
 Item 9 (sexual difficulties) 1.125 351.1 309 0.0498 1.132 1.212 Gender (U) Age
 Item 10 (treatment difficulties) − 0.144 288.9 309 0.788 0.932 0.942 – Age
Gender
NRRs coded as missing
 Item 1 (itchy/sore/painful/stinging) − 0.743 342.1 309 0.094 1.104 1.098 Age (U) Gender
 Item 2 (embarrassed/self conscious) − 0.262 234.2 309 0.999 0.755 0.768 Gender (U) Age
 Item 3 (shopping/home/gardening) 1.110 202.9 305 1.000 0.663 0.735 Age (U)
Gender (U)
–
 Item 4 (clothes) − 0.038 326.5 307 0.212 1.060 0.975 Gender (U) Age
 Item 5 (social/leisure activities) 0.157 169.0 300 1.000 0.561 0.598 – Age
Gender
 Item 6 (sport) 0.412 207.6 214 0.611 0.965 0.949 Gender (U) Age
 Item 7 (working/studying) 0.825 299.8 264 0.064 1.131 1.036 – Age
Gender
 Item 8 (interpersonal problems) 0.895 249.6 293 0.969 0.849 0.922 – Age
Gender
 Item 9 (sexual difficulties) 1.095 263.9 247 0.220 1.064 1.261 Age (nU) Gender
 Item 10 (treatment difficulties) 0.001 290.2 305 0.720 0.948 0.955 – Age
Gender
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(interpersonal problems) and 7 (working/studying) when 
missing-scoring NRRs.
Item invariance
With zero-scoring NRRs, six and three items showed DIF 
for gender and age, respectively (Table 2). A uniform DIF 
was found in the majority of instances. Items 3 (shopping/
home/gardening) and 6 (sport) were the only items to dem-
onstrate DIF for both demographic variables. Items 7 (work-
ing/studying), 8 (interpersonal problems) and 10 (treatment 
difficulties) were free from DIF. With missing-scoring 
NRRs, four and three items indicated DIF for gender and 
age, respectively. Items 5 (social/leisure activities), 7 (work-
ing/studying), 8 (interpersonal problems) and 10 (treatment 
difficulties) were free from DIF.
Fig.3  Item characteristic curves (ICC) for DLQI items 6, 7 and 9. 
The latent trait (i.e. HRQoL impairment) is measured along axis x, 
while axis y indicates the probability of endorsing an item. The point 
on axis x at which the curve for an item crosses the 0.5 probability 
level on axis y serves as an index of item difficulty indicating where 
50% of the patients endorse a given item. Items with lower item diffi-
culty values are considered to be ‘easier’ and expected to be endorsed 
at lower HRQoL impairment [14]. Curves: ‘0 scoring’ NRRs: black: 
0 (‘not at all’ or ‘not relevant’), red: 1 (‘a little’), green: 2 (‘a lot’), 
blue: 3 (‘very much’). ‘Missing scoring’: black: 0 (‘not at all’), red: 
1 (‘a little’), green: 2 (‘a lot’), blue: 3 (‘very much’). DLQI Derma-
tology Life Quality Index, HRQoL health related quality of life, 
NRR ‘not relevant’ response
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Discussion
Rasch models have previously been applied to investigate the 
psychometrics of the DLQI in various patient populations, 
including psoriasis, atopic dermatitis, hand eczema, neu-
rodermatitis and chronic arsenic exposure [15–21, 38]. Yet 
this is the first study to evaluate measurement functioning 
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of the DLQI using a Rasch model considering both possible 
interpretations of NRRs.
Our most important finding is that psychometric prop-
erties of DLQI can largely vary depending on how NRRs 
are interpreted. While aspects related to patients, such as 
person fit and person separation reliability indices were 
similar when zero-scoring and missing-scoring NRRs, 
substantial differences were seen at item level. These dif-
ferences are visible in terms of item locations, item fit, 
response scale and invariance. The items with the highest 
proportion of NRRs [6 (sport), 7 (working/studying) and 
9 (sexual difficulties)] performed particularly weakly in 
the Rasch model. These items suffered from item mis-
fit and item-level disordering. It seems that NRRs are 
responsible for the majority of item misfit and disordering. 
Treating NRRs as missing accommodated the disorder-
ing of response categories and also increased the differ-
ence between them. This interpretation of NRRs has also 
reduced the DIF observed.
Results of previous attempts to investigate the psycho-
metrics of the DLQI using a Rasch model somewhat differ 
from our findings. The person separation reliability values 
(0.910–0.914) in this study were modestly higher than those 
from former studies (range: 0.82–0.88) [17, 19]. Twiss et al. 
reported that items 2 (embarrassed/self conscious) and 7 
(working/studying) misfitted the model and items 6 (sport), 
7 (working/studying), 8 (interpersonal problems) and 9 (sex-
ual difficulties) indicated a disordered response threshold 
in psoriasis patients [19]. In their study, items 2 (embar-
rassed/self conscious), 4 (clothes), 6 (sport) and 8 (inter-
personal problems) exhibited DIF by gender and items 5 
(social/leisure activities) and 10 (treatment difficulties) by 
age. Another study with psoriasis patients by Nijsten et al. 
reported all DLQI items to display DIF by culture, but no 
items by age or gender [17]. In contrast, with zero-scoring 
NRRs, we detected the presence of DIF in items 2 (embar-
rassed/self conscious), 3 (shopping/home/gardening), 4 
(clothes), 5 (social/leisure activities), 6 (sport) and 9 (sex-
ual difficulties) by gender and in items 1 (itchy/sore/pain-
ful/stinging), 3 (shopping/home/gardening), and 6 (sport) 
by age. No matter how NRRs are interpreted, our findings 
confirm that the DLQI performs poorly in terms of establish-
ing measurement invariance across subgroups of patients. 
The lack of measurement equivalence highlights that there 
may be important differences in how certain groups (e.g. 
males vs. females or younger vs. older) tend to interpret most 
DLQI items, and therefore, the differences detected between 
known-groups of patients should be treated with caution.
Available data are controversial with regard to the dimen-
sionality of DLQI: in accordance with our results some stud-
ies provided evidence supporting its unidimensionality [15, 
21], while other studies revealed a multidimensional struc-
ture of the scale [16, 19, 20, 39]. Unidimensionality cannot 
be assessed without considering the content of the instru-
ment [40, 41]. DLQI undoubtedly covers numerous aspects 
of HRQoL; even the developers suggest that the DLQI can 
be analysed under the following six subscales: symptoms 
and feelings (items 1 and 2), daily activities (items 3 and 4), 
leisure (items 5 and 6), work and school (item 7), personal 
relationships (items 8 and 9) and treatment (item 10) [2]. 
It may be argued that all these concepts underlie different 
constructs and a total score may not be calculated by sum-
ming the individual items. Thus, while our study confirmed 
the psychometrically unidimensional nature of the DLQI, 
subsequent studies are warranted to further investigate this 
finding.
Our findings have important implications for clinical 
practice and research. NRRs may lead to bias in the assess-
ment of HRQoL and preclude meaningful comparisons 
across psoriasis patients. In numerous national guidelines 
on systemic treatment, psoriasis is considered moderate-to-
severe if the patient has a PASI ≥ 10 and DLQI > 10, and 
a ≥ 5-point decrease in DLQI marks an adequate treatment 
response [42–44]. This latter is based on the average mini-
mal clinically important difference of four points in inflam-
matory skin conditions [1, 45–48]. Given the central role 
of DLQI in these criteria, providing evidence of robust 
measurement properties is essential. It seems, however, that 
NRRs lead to measurement bias in the DLQI suggesting that 
scores of patients with at least one compared to no NRRs 
should not be compared. In the most extreme instance, by 
ignoring NRRs, one may risk underdiagnosis and even 
undertreatment of patients with moderate-to-severe psoria-
sis. Furthermore, consistently with previous Rasch models 
[15, 16, 19], the DLQI showed a limited ability to measure 
HRQoL in patients with very mild and extremely severe 
HRQoL impairment, since there are no items for patients 
with the worst and best HRQoL. The DLQI thus may need 
some more easy and difficult items (more and less likely 
endorsed, respectively), to achieve a better person-item tar-
geting and be able to better discriminate between patients.
The better measurement performance of the DLQI 
with missing-scoring suggests that scoring NRRs equal 
Fig.4  Person-item maps. Each map has two panels, the upper panel 
shows the histogram of patients’ HRQoL impairment estimates, while 
the lower panel indicates the locations of items ordered in relation to 
their difficulty using a logit scale. The items that are the easiest to 
endorse are positioned on the left and the most difficult (i.e. require 
more impairment in HRQoL to endorse) items are located in the 
right. Items should ideally be located along the whole scale to mean-
ingfully measure the HRQoL impairment across the entire spectrum 
of patients. dlqi_1 = itchy/sore/painful/stinging; dlqi_2 = embarrassed/
self conscious; dlqi_3 = shopping/home/gardening; dlqi_4 = clothes; 
dlqi_5 = social/leisure activities; dlqi_6 = sport; dlqi_7 = working/
studying; dlqi_8 = interpersonal problems; dlqi_9 = sexual difficulties; 
dlqi_10 = treatment difficulties. *Response options are disordered. 
HRQoL health related quality of life NRR ‘not relevant’ response
◂
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to ‘not at all’ responses may be incorrect, as NRRs seem 
to represent a mixture of the other four response catego-
ries of the DLQI. A promising approach to resolve bias 
associated with NRRs may be an alternative scoring of the 
DLQI, the DLQI-R [12]. DLQI-R, in fact, missing-scores 
all NRRs and then replaces them with the average score 
of the relevant items. By this, the DLQI-R establishes a 
common ground to compare HRQoL of patients with at 
least one vs. no NRRs or of those ticking NRRs on differ-
ent DLQI items. In the past three years, a growing number 
of observational studies reported the DLQI-R in psoriasis, 
pemphigus, morphea, vitiligo and hidradenitis suppurativa 
patients [46, 49–53]. Additionally, it is used as a primary 
endpoint in ongoing clinical studies with an interleukin-23 
blocker, tildrakizumab for the treatment of psoriasis [54, 
55]. Although the DLQI-R is equally good or even better 
in many aspects of measurement properties than the DLQI 
[12, 52, 53], it cannot settle all issues around the underly-
ing construct of the original questionnaire (e.g. DIF).
One of the strengths of this study is that it included 
a heterogeneous study population that covered the full 
spectrum of psoriasis patients of varying age, gender, 
type of psoriasis and disease severity. We used a Rasch 
model analysis that represent a state-of-the-art technique 
for questionnaire development and validation [14]. Limi-
tations of this study include the following. Referral bias 
cannot be ruled out, as both cross-sectional surveys were 
carried out at two academic dermatology clinics where 
more severe patients are referred to. Selection bias may 
also arise, since nearly half of the patients were treated 
with biologics as a preset inclusion criteria in one of the 
cross-sectional surveys [22]. This study used the Hungar-
ian version of the DLQI, and thus, caution is warranted in 
generalising the results to other diagnoses and cultures. 
Lastly, a partial credit model was employed in the present 
study; nevertheless, other modelling approaches may be 
more suitable for other samples.
In conclusion, measurement performance of the DLQI 
varies depending on how NRRs are interpreted. It seems that 
NRRs should be treated as missing responses that signifi-
cantly improve measurement properties, including item fit, 
response ordering and measurement invariance. These find-
ings give further empirical support for the use of the DLQI-
R scoring modification. Further research efforts need to be 
directed towards making effective revisions of the DLQI as 
well as standardizing HRQoL measurement in dermatology.
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